Fluoxetine inhibits desipramine metabolism
| Autor: | Joseph Biederman, James G. Flood, Ross J. Baldessarini, Timothy E. Wilens, McDermott Sp, P R Puopolo |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
chemistry.chemical_classification
Fluoxetine Depressive Disorder business.industry Desipramine dose Desipramine Metabolism Pharmacology Psychiatry and Mental health Arts and Humanities (miscellaneous) chemistry Attention Deficit Disorder with Hyperactivity Medicine Humans Drug Interactions Drug Therapy Combination business Active metabolite medicine.drug Tricyclic Retrospective Studies |
| Zdroj: | Archives of general psychiatry. 49(9) |
| ISSN: | 0003-990X |
| Popis: | To the Editor.— We read with interest the article by Nelson et al 1 on the treatment of depression with fluoxetine and desipramine, particularly regarding effects of fluoxetine on serum levels of desipramine and its major active metabolite, 2-hydroxydesipramine. Fluoxetine can elevate blood concentrations and the risk of toxic effects of tricyclic antidepressants unless their dose is greatly restricted. 2,3 This interaction probably reflects competition for enzymatic oxidation. 4 Although ring-hydroxylation to 2-hydroxydesipramine is a major route of metabolism of desipramine, assessment of effects of fluoxetine on 2-hydroxydesipramine is very limited. 2-4 In a retrospective comparison of 14 adults with depression given desipramine and fluoxetine and 52 patients given desipramine alone, Nelson et al 1 found serum desipramine levels to be similar in both groups despite an approximate reduction of 30% in desipramine dose with fluoxetine. In their data, we find (eg, at 4 weeks of fixed-dose treatment) lower mean |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|